ThunderBio Innovation Limited

ThunderBio Innovation Limited is a company founded in 2018 by scientists from Hong Kong University of Science and Technology. The company is focused on leveraging cutting-edge droplet microfluidic technology to advance the field of precision medicine. Operating with R&D centers in Shenzhen, Hong Kong, and Jiaxing, ThunderBio has placed emphasis on the establishment of a substantial 2,800m GMP for consumables, instruments, and reagents manufacture in Jiaxing. With a core focus on digital PCR and single cell sequencing, ThunderBio's platform technologies cater to high-end research and diagnostic use, particularly in areas such as early cancer screening and detection, cell and gene therapy, non-invasive prenatal diagnosis, viral load quantification, and high-throughput drug/antibody screening. Notably, the company secured a CNY100.00M Series B investment on 04 January 2024, in a round led by Guangzhou Financial Holding Fund Management, 鲁信创业投资集团股份有限公司, 深圳市道合科技投资管理有限公司, Zhuopu Touzi, and Shenzhen Chenmuyun Technology. ThunderBio stands as a leader in manufacturing and is headquartered in China. Its commitment to disruptive technology and advancing precision medicine underscores its potential for continued growth and impact.